CoChat
Sign Up
Cited by 516Sepsis Diagnosis and TreatmentImmune Response and InflammationInflammation biomarkers and pathways

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis*

Open access
Rice, Todd W., Wheeler, Arthur P., Bernard, Gordon R., Vincent, Jean-Louis, Angus, Derek C., Aikawa, Naoki, Demeyer, Ignace, Sainati, Stephen, Amlot, Nicholas, Cao, Charlie, Ii, Masayuki, Matsuda, Hideyasu, Mouri, Kouji, Cohen, Jon·2010·Critical Care Medicine
DOI 10.1097/ccm.0b013e3181e7c5c9
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To evaluate whether TAK-242, a small-molecule inhibitor of Toll-like receptor-4-mediated signaling, suppresses cytokine levels and improves 28-day all-cause mortality rates in patients with severe sepsis. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: A total of 93 intensive care units worldwide. PATIENTS: A total of 274 patients with severe sepsis and shock or respiratory failure. INTERVENTIONS: Patients were randomly assigned to receive a 30-min loading dose followed by 96-hr infusions of placebo, TAK-242 1.2 mg/kg/day, or TAK-242 2.4 mg/kg/day. MEASUREMENTS AND MAIN RESULTS: The primary pharmacodynamic end point was change in serum interleukin-6 levels relative to baseline, with 28-day all-cause mortality rate the primary clinical end point. The trial was terminated because of a lack of effect of TAK-242 in suppressing serum interleukin-6 levels. A total of 274 subjects were randomly assigned and treated. Clinical parameters at baseline were balanced across the three groups. TAK-242 did not suppress interleukin-6 as measured by 0- to 96.5-hr area under the interleukin-6 concentration curve at either dose. Specifically, the area under the effect curve increased by 9% and 26.9% in the TAK-242 1.2 and 2.4 mg/kg/day groups, respectively, which was not statistically different from placebo (p = .63 and .15, respectively). The 28-day mortality rate was 24% in the placebo, 22% in the low-dose, and 17% in the high-dose group (p = .26 for placebo vs. high dose). A nonsignificant reduction in mortality rate was observed in a subset of patients with both shock and respiratory failure (placebo [n = 51], 33%, vs. high dose [n = 52], 19%, p = .10). Transient, dose-related increases in methemoglobin levels were observed with TAK-242 treatment in 30.1% of the patients. CONCLUSIONS: TAK-242 failed to suppress cytokine levels in patients with sepsis and shock or respiratory failure. Treatment with TAK-242 resulted in mild increases in serum methemoglobin levels but was otherwise well tolerated. Although observed mortality rates in patients with both shock and respiratory failure were lower with the 2.4 mg/kg/day dose, differences were not significant.

Overview

Integrity signals

Registry

Crossref · 10.1097/ccm.0b013e3181e7c5c9

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 59 references

Research works printed but not linked: 3

  1. Feterowski, 2003, Immunology, 169, 2823
  2. Cinel, 2009, Crit Care Med, 37, 291, 10.1097/CCM.0b013e31819267fb · DOI
  3. Ellingsen, 2002, Med Sci Monit, 8, BR149

Cited by

Sorted by citations

Items 201–300 of 516

Related

See all

Metadata

Authors
Rice, T. W., Wheeler, A. P., Bernard, G. R., Vincent, J.-L., Angus, D. C., Aikawa, N., Demeyer, I., Sainati, S., Amlot, N., Cao, C., Ii, M., Matsuda, H., Mouri, K., & Cohen, J.
Affiliations
Vanderbilt University (US)
ORCID
Venue
Critical Care Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-08
Volume
38
Issue
8
Pages
1685-1694
ISSN
0090-3493 (ISSN-L)
DOI
10.1097/ccm.0b013e3181e7c5c9
OpenAlex
W2053189438
Cited by
512
References
59
Citations by year
2026: 34 · 2025: 37 · 2024: 35 · 2023: 35 · 2022: 38 · 2021: 45 · 2020: 49 · 2019: 38 · 2018: 36 · 2017: 30 · 2016: 25 · 2015: 16 · 2014: 23 · 2013: 25 · 2012: 27
FWCI
16.99
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords
sepsis, interleukin-6, cytokine inhibition, septic shock, respiratory failure, 28-day mortality, methemoglobinemia, drug safety, intensive care unit patients, dose comparison, pharmacodynamics
MeSH terms
Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Male, Middle Aged, Multiple Organ Failure, Probability, Reference Values, Sulfonamides, Survival Analysis, Cytokines, Treatment Outcome, Hospital Mortality, Risk Assessment, Sepsis, Pulse Therapy, Drug

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review